Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Hydroxyurea  (2)
  • 99m-Tc-Pertechnat  (1)
  • 99m-Tc-Pertechnetate  (1)
  • 1
    Electronic Resource
    Electronic Resource
    The use of 99m-Tc-Pertechnetate for the determination of red cell volume (1973)
    Springer
    Journal of molecular medicine 51 (1973), S. 141-142 
    Details
    ISSN: 1432-1440
    Keywords: Blood volume ; 99m-Tc-Pertechnetate ; 99m-Tc-Pertechnat ; Blutvolumen
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung Es wurden Untersuchungen zur Bestimmung des Erythrocytenvolumens beim Menschen mit dem kurzlebigen Isotop 99m-Tc durchgeführt. Dabei zeigte sich, daß eine ausreichend stabile Markierung durch halbstündige Inkubation mit 99m-Tc und anschließende kurzzeitige Zugabe von SnCl2 erreicht werden kann. Die Inkorporationsrate ist vom Plasmaanteil und vom Hämatokrit der zu markierenden Erythrocytensuspension abhängig. Gleichzeitige Markierung derselben oder einer gleichen Probe mit51Cr ergab gut übereinstimmende Resultate für das Erythrocytenvolumen.
    Notes: Summary Incubation of human red cells with 99 m-Tc and subsequent addition of SnCl2 resulted in stable red cell labeling. Simultaneous tagging of the same or another red cell specimen by51Cr and calculation of the red cell volume from both isotopes gave almost identical results. The 99m-Tc-technique may become the method of choice for red cell volume determination.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01483924
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Interferon in chronic myeloid leukemia (1993)
    Springer
    Annals of hematology 67 (1993), S. 101-106 
    Details
    ISSN: 1432-0584
    Keywords: Chronic myeloid leukemia ; Interferon ; Hydroxyurea ; Busulfan ; Bone marrow transplantation
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary The therapeutic efficacy of interferon-alpha (IFN-α) in the treatment of chronic myeloid leukemia is currently being tested in a number of institutional, interinstitutional, and international trials. There is no doubt that responses are achieved in many patients, and in a small subset complete eradication of clonogenic cells may be possible. However, it has not yet been shown that overall survival of patients treated with IFN-α is better than that of those treated with conventional cytoreductive drugs. There are still controversial opinions on problems such as dosages and duration of treatment, combination with cytostatic agents, definition of responses, and relevance of cytogenic and molecular data. An international workshop discussed the data on interferon therapy and attempted to define the role of interferon today in the management of chronic myeloid leukemia.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01788134
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 3
    Electronic Resource
    Electronic Resource
    A phase I/II study of recombinant interferon alpha 2a and hydroxyurea for chronic myelocytic leukemia (1989)
    Springer
    Annals of hematology 58 (1989), S. 275-278 
    Details
    ISSN: 1432-0584
    Keywords: Chronic myelocytic leukemia ; Hydroxyurea ; r-interferon-alpha 2a
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Nine previously untreated patients with Philadelphia chromosome-positive chronic myelocytic leukemia (CML) were treated with recombinant interferon alpha 2a (rIFN-alpha 2a) and hydroxyurea. Patients received 6×106 U rIFN-alpha 2a daily for the first week and 3×106 U rIFN-alpha 2a daily for the second week. As maintenance treatment starting on day 15, patients received 3×106 U rIFN-alpha 2 a 3 times a week. Simultaneously, hydroxyurea was given, starting at a dose of 40 mg/kg on day one. The maintenance dosage was adjusted to the white blood cell count. Two patients responded with complete hematological remissions but without cytogenetic and molecular-genetic improvements. Seven patients responded with partial hematological remissions. Response to therapy was rapid; normal white blood cell counts were reached after a median of 12 days. The doses of rIFN-alpha 2a and hydroxyurea needed to keep the leucocyte count in the normal range were low (3×106 U rIFN-alpha 2a 3 times per week, 0.5–1.5 g hydroxyurea/day). Acute toxicity of the combination therapy consisted of fever (9 of 9 patients), flulike symptoms (7 of 9 patients), pruritus and/or rash (3 of 9 patients) and evidence of a tumor cell lysis syndrome (1 of 9 patients). The side effects were not dose-limiting. Combination therapy with rIFN-alpha 2a and hydroxyurea for CML is well tolerated and allows quick and effective hematological control of the disease.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00320165
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...